Ambrilia Biopharma Inc'

1
Ambrilia Biopharma Inc. Monique
Létourneau Executive Vice-President CFO
September 21, 2007
2
This presentation contains forward-looking
statements that reflect the Companys current
expectation regarding future events. The
forward-looking statements involve risks and
uncertainties. Actual events could differ
materially from those projected herein and depend
on a number of factors including, but not limited
to, changing market conditions, successful and
timely completion of clinical studies,
uncertainties related to the regulatory approval
process, establishment of corporate alliances and
other risks detailed from time to time in the
Companys filings. Such statements are also based
on various assumptions, including the successful
and timely completion of clinical studies on
Ambrilias products demonstrating efficacy and
safety for human use, their successful
commercialization within the forecasted timelines
and the attainment of the forecasted milestone
payments and other revenues. While Ambrilia
anticipates that subsequent events and
developments may cause Ambrilias views to
change, Ambrilia specifically disclaims any
obligation to update these forward-looking
statements, unless obligated to do so by
applicable securities laws.
Ambrilias Forward-Looking Statements
3
Ambrilia Biopharma

• A TSX-listed (TAMB) biotechnology company
  focused on discovery and development of novel
  treatments for viral diseases and cancer
• Resulting from merger of Procyon and Cellpep
• Adding late-stage programs to rich portfolio of
  innovative products
• Head office, RD and manufacturing facilities
  located in Montreal
• Regional office in France
• 44 employees

4
Highlights

• Risk-adjusted pipeline of multiple drug
  candidates
• 2 low-risk reformulated drugs
• Octreotide An improved prolonged-release
  formulation of
• Novartis SandostatinLAR for treatment of
• acromegaly
• Goserelin A potential first-to-market generic
  of Astra-Zenecas
• ZoladexPR for the treatment of prostate
  cancer
• 3 Anti-Viral Programs
• HIV Protease Inhibitor Program With potential
  best-in-class lead
• compound PPL-100

5
Highlights (continued)

• Risk-adjusted pipeline of multiple drug
  candidates
• 3 Anti-Viral Programs (continued)
• HIV Integrase Inhibitor Program A new series of
  compounds with
• potentially a distinct resistance profile than
  that of integrase
• inhibitors currently in clinical development
• Other Anti-Viral Programs Lead compounds in
  HIV/AIDS, Hep C
• and Influenza
• Other Anti-Cancer Drugs
• PCK3145 A therapeutic peptide with a novel
  mechanism of action
• to treat advanced prostate cancer
• Others TVT Delivery Technology for solid tumors

6
Ambrilias Pipeline
(1)
(2)
(1) Licensed to Mallinckrodt (U.S.), TEVA
(France, Germany, Benelux, Spain and
Scandinavia), and others (2) Licensed to Merck
Co., Inc.
7
Highlights (continued)

• Strong Partners
• US 229 M licensing deal for PPL-100 (US 17 M
  
• upfront, plus royalties)
• Potential additional payments and royalties on
  development of each
• related compound
• Licensing partners for Octreotide (U.S. and
  main E.U. countries)
• Other licensing partners for the rest of the
  world

8
Ambrilia Financial Snapshot
9
Ambrilia Near-Term Value Drivers

• Octreotide
• Phase III data Q1/08
• Potential launch in 2009
• Goserelin
• Potential licensing partnership in 2008
• Potential launch in 2010
• PPL-100
• Ongoing clinical development by Merck Co.
• PCK3145
• Potential partnership

10
A Montreal-based, biopharmaceutical company
dedicated to the discovery and developement of
novel treatments for viral diseases and
cancer (TSXAMB)